Sight Sciences SGHT 深 沪
等待开盘 10-26 09:30:00 美东时间
8.99
-0.100
-1.10%
华盛通- 最 高9.2599
- 今 开9.08
- 成交量 34.09万股
- 最 低 8.74
- 昨 收 9.09
- 总市值 49.52万
- 52周最高 9.7126
- 市盈率 静 --
- 换手率 0.62%
- 52周最低 3.378
- 委 比 -31.43%
- 总股本 5.51万
- 历史最高 42.57
- 量 比 1.53
- 振 幅 5.72%
- 历史最低 1.04
- 每 手 1
- 风险率 1.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sight Sciences收跌5.91%，成交额242.48万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:12
美股大行评级 | 潜在涨幅279.75%！Jones Trading维持Contineum Therapeutics(CTNM)"买入"评级，目标价上调至30美元
今日重点评级关注：Jones Trading：维持Contineum Therapeutics"买入"评级，目标价从24美元升至30美元；StoneX：维持Forum Markets"投机性买入"评级，目标价从9美元升至12美元
10-16 12:30
Why Is Sight Sciences Stock Gaining Thursday?
Sight Sciences, Inc. (NASDAQ:SGHT) stock gained Thursday after H.C. Wainwright initiated coverage with a Buy rating and a $14 price forecast. Analyst Yi Chen sees upside potential from the medical device company’s expanding glaucoma and dry eye treatment businesses, supported by improving operating ...
10-16 01:53
HC Wainwright & Co. Initiates Coverage On Sight Sciences with Buy Rating, Announces Price Target of $14
HC Wainwright & Co. analyst Yi Chen initiates coverage on Sight Sciences (NASDAQ:SGHT) with a Buy rating and announces Price Target of $14.
10-15 18:54
Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
Sight Sciences announced the commercial launch of the OMNI® Ultra Surgical System, an advanced glaucoma treatment technology, at the 2026 American Academy of Ophthalmology meeting. The OMNI Ultra enhances the company's implant-free, minimally invasive glaucoma surgery platform with improved versatility and procedural control. Key features include single-pass canaloplasty, TruSync™ Plus technology, and expanded treatment options for varying diseas...
10-01 11:05
Sight Sciences Announces Updated FDA Indications For TearCare, Effective August 18
Indications for Use state: "The Sight Sciences TearCare System is a thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the me...
08-19 19:10
Sight Sciences Appoints New Chief Legal Officer Rashid
The latest update is out from Sight Sciences ( ($SGHT) ). On August 6, 2026, Si...
08-10 20:59
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
UBS Maintains Buy on Sight Sciences, Raises Price Target to $8
UBS analyst Patrick Wood maintains Sight Sciences (NASDAQ:SGHT) with a Buy and raises the price target from $7 to $8.
08-07 03:40
